A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
710 patients around the world
Available in Argentina, Brazil
Depression is a common and serious psychiatric disorder which is a leading cause of
disability worldwide and is associated with elevated mortality and suicide risk.
Aticaprant (JNJ-67953964) is a once daily, highly selective kappa opioid receptor (KOR)
antagonist, with demonstrated selectivity over mu opioid receptor (MOR) and delta opioid
receptor (DOR) being developed for adjunctive treatment of MDD with ANH+. The total
duration of the study will be up to 87 days. Safety evaluation including adverse events,
physical examinations, urine drug test, alcohol breath tests and clinical laboratory
tests will be assessed at specific time points during this study.